Christian Schmidt-Lauber1, Christian Günster2, Tobias B Huber1, Melissa Spoden2, Florian Grahammer1,3. 1. III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 2. Research Institute of the Local Health Care Funds (WIdO), Berlin, Germany. 3. University Transplant Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Abstract
Background: Collateral effects and consequences of the coronavirus disease 19 (COVID-19) pandemic on kidney transplant recipients remain widely unknown. Methods: This retrospective cohort study examined changes in admission rates, incidences of diseases leading to hospitalization, in-patient procedures, and maintenance medication in long-term kidney transplant recipients with functioning graft during the early COVID-19 pandemic in Germany. Data were derived from a nationwide health insurance database. Analysis was performed from March 15 to September 30 and compared the years 2019 and 2020. Effects on mortality and adverse allograft events were compared with COVID-19-attributed effects. Results: A total of 7725 patients were included in the final analysis. Admissions declined in 2020 by 17%, with the main dip during a 3-month lockdown (-31%) but without a subsequent rebound. Incidences for hospitalization did not increase for any investigated disease entities, whereas decreasing trends were noted for non-COVID-19 pulmonary and urogenital infections (incidence rate ratio 0.8, 95% CI, 0.62 to 1.03, and 0.82, 95% CI, 0.65 to 1.04, respectively). Non-COVID-19 hospital stays were 0.6 days shorter (P=0.03) and not complicated by increased dialysis, ventilation, or intensive care treatment rates. In-hospital and 90-day mortality remained stable. Incidences of severe COVID-19 requiring hospitalization was 0.09 per 1000 patient-days, and in-hospital mortality was 9%. A third (31%) of patients with calcineurin-inhibitor medication and without being hospitalized for COVID-19 reduced doses by at least 25%, which was associated with an increased allograft rejection risk (adjusted hazard ratio 1.29, 95% CI, 1.02 to 1.63). COVID-19 caused 17% of all deaths but had no significant association with allograft rejections. All-cause mortality remained stable (incidence rate ratio 1.15, 95% CI, 0.91 to 1.46), also when restricting analysis to patients with no or outpatient-treated COVID-19 (0.97, 95% CI, 0.76 to 1.25). Conclusion: Despite significant collateral effects, mortality remained unchanged during the early COVID-19 pandemic. Considerable temporary reductions in admissions are safe, whereas reducing immunosuppression results in increased allograft rejection risk.
Background: Collateral effects and consequences of the coronavirus disease 19 (COVID-19) pandemic on kidney transplant recipients remain widely unknown. Methods: This retrospective cohort study examined changes in admission rates, incidences of diseases leading to hospitalization, in-patient procedures, and maintenance medication in long-term kidney transplant recipients with functioning graft during the early COVID-19 pandemic in Germany. Data were derived from a nationwide health insurance database. Analysis was performed from March 15 to September 30 and compared the years 2019 and 2020. Effects on mortality and adverse allograft events were compared with COVID-19-attributed effects. Results: A total of 7725 patients were included in the final analysis. Admissions declined in 2020 by 17%, with the main dip during a 3-month lockdown (-31%) but without a subsequent rebound. Incidences for hospitalization did not increase for any investigated disease entities, whereas decreasing trends were noted for non-COVID-19 pulmonary and urogenital infections (incidence rate ratio 0.8, 95% CI, 0.62 to 1.03, and 0.82, 95% CI, 0.65 to 1.04, respectively). Non-COVID-19 hospital stays were 0.6 days shorter (P=0.03) and not complicated by increased dialysis, ventilation, or intensive care treatment rates. In-hospital and 90-day mortality remained stable. Incidences of severe COVID-19 requiring hospitalization was 0.09 per 1000 patient-days, and in-hospital mortality was 9%. A third (31%) of patients with calcineurin-inhibitor medication and without being hospitalized for COVID-19 reduced doses by at least 25%, which was associated with an increased allograft rejection risk (adjusted hazard ratio 1.29, 95% CI, 1.02 to 1.63). COVID-19 caused 17% of all deaths but had no significant association with allograft rejections. All-cause mortality remained stable (incidence rate ratio 1.15, 95% CI, 0.91 to 1.46), also when restricting analysis to patients with no or outpatient-treated COVID-19 (0.97, 95% CI, 0.76 to 1.25). Conclusion: Despite significant collateral effects, mortality remained unchanged during the early COVID-19 pandemic. Considerable temporary reductions in admissions are safe, whereas reducing immunosuppression results in increased allograft rejection risk.
Authors: Jacob Bodilsen; Peter Brønnum Nielsen; Mette Søgaard; Michael Dalager-Pedersen; Lasse Ole Zacho Speiser; Troels Yndigegn; Henrik Nielsen; Torben Bjerregaard Larsen; Flemming Skjøth Journal: BMJ Date: 2021-05-24
Authors: Milena Gianfrancesco; Kimme L Hyrich; Jinoos Yazdany; Pedro M Machado; Philip C Robinson; Sarah Al-Adely; Loreto Carmona; Maria I Danila; Laure Gossec; Zara Izadi; Lindsay Jacobsohn; Patricia Katz; Saskia Lawson-Tovey; Elsa F Mateus; Stephanie Rush; Gabriela Schmajuk; Julia Simard; Anja Strangfeld; Laura Trupin; Katherine D Wysham; Suleman Bhana; Wendy Costello; Rebecca Grainger; Jonathan S Hausmann; Jean W Liew; Emily Sirotich; Paul Sufka; Zachary S Wallace Journal: Ann Rheum Dis Date: 2020-05-29 Impact factor: 19.103
Authors: Lorenz A Kapsner; Marvin O Kampf; Susanne A Seuchter; Julian Gruendner; Christian Gulden; Sebastian Mate; Jonathan M Mang; Christina Schüttler; Noemi Deppenwiese; Linda Krause; Daniela Zöller; Julien Balig; Timo Fuchs; Patrick Fischer; Christian Haverkamp; Martin Holderried; Gerhard Mayer; Holger Stenzhorn; Ana Stolnicu; Michael Storck; Holger Storf; Jochen Zohner; Oliver Kohlbacher; Adam Strzelczyk; Jürgen Schüttler; Till Acker; Martin Boeker; Udo X Kaisers; Hans A Kestler; Hans-Ulrich Prokosch Journal: Front Public Health Date: 2021-01-13
Authors: Sunjae Bae; Mara A McAdams-DeMarco; Allan B Massie; JiYoon B Ahn; William A Werbel; Daniel C Brennan; Krista L Lentine; Christine M Durand; Dorry L Segev Journal: Transplantation Date: 2021-01-01 Impact factor: 5.385
Authors: Gwilym J Webb; Thomas Marjot; Jonathan A Cook; Costica Aloman; Matthew J Armstrong; Erica J Brenner; Maria-Andreea Catana; Tamsin Cargill; Renumathy Dhanasekaran; Ignacio García-Juárez; Hannes Hagström; James M Kennedy; Aileen Marshall; Steven Masson; Carolyn J Mercer; Ponni V Perumalswami; Isaac Ruiz; Sarang Thaker; Nneka N Ufere; Eleanor Barnes; Alfred S Barritt; Andrew M Moon Journal: Lancet Gastroenterol Hepatol Date: 2020-08-28
Authors: Chiara Cantarelli; Andrea Angeletti; Laura Perin; Luis Sanchez Russo; Gianmarco Sabiu; Manuel Alfredo Podestà; Paolo Cravedi Journal: Clin Kidney J Date: 2022-07-27